Health Condition 1: C249- Malignant neoplasm of biliary tract, unspecified Health Condition 2: C23- Malignant neoplasm of gallbladder Health Condition 3: C228- Malignant neoplasm of liver, primary, unspecified as to type Health Condition 4: C259- Malignant neoplasm of pancreas, unspecified Health Condition 5: C169- Malignant neoplasm of stomach, unspecified Health Condition 6: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung
Conditions
Interventions
Intervention1: olanzapine with nutritional advice: 1.Tab. olanzapine 2.5mg once a day for 12 weeks
2.Nutritional advice in detail which includes type and quantity of diet to be taken and individualiz
Sponsors
Jawaharlal Institute of Postgraduate Medical Education and Reseach
Eligibility
Inclusion criteria
Inclusion criteria: stage 3 or 4 of Gastric Hepatopancreaticobiliary and lung cancer, who are fit for chemotherapy and are able to take oral diet
Exclusion criteria
Exclusion criteria: a. Patients on adjuvant chemotherapy b. Patients with concurrent radiotherapy c. Intake of olanzapine for more than 4 days per month for any other indications d. On any antipsychotic or antidepressants e. Use of systemic corticosteroids (prednisolone 5mg or equivalent for more than 7 days in the previous 4 weeks) f. Ascites at time of enrolment g. Pregnancy h. Patients already enrolled in other trails within the past 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change in body weight and symptoms of anorexiaTimepoint: At 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary End Points: Improvement in QoL, FAACT A/CS, VAS Improvement in the skeletal muscle index at third lumbar vertebra Chemotherapy outcomes and toxicityTimepoint: At 12 weeks | — |
Countries
India
Contacts
Public ContactPrasanth Ganesan
Jawaharlal Institute of Postgraduate Medical Education and Research
Outcome results
None listed